Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded up 6.2% during mid-day trading on Monday . The company traded as high as $25.92 and last traded at $25.09. 751,287 shares changed hands during trading, an increase of 160% from the average session volume of 288,986 shares. The stock had previously closed at $23.62.

A number of equities research analysts recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $32.50.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01).

In other news, insider Susan E. Barrowcliffe sold 15,000 shares of Aimmune Therapeutics stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $20.26, for a total transaction of $303,900.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at approximately $303,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mary M. Rozenman sold 45,060 shares of Aimmune Therapeutics stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $20.85, for a total value of $939,501.00. Following the transaction, the insider now owns 30,129 shares in the company, valued at approximately $628,189.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 187,460 shares of company stock worth $4,023,298. 24.56% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 499 shares during the period. Teachers Advisors LLC raised its holdings in shares of Aimmune Therapeutics by 2.4% during the 4th quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock worth $884,000 after acquiring an additional 1,025 shares during the period. American International Group Inc. raised its holdings in shares of Aimmune Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after acquiring an additional 1,070 shares during the period. Legal & General Group Plc raised its holdings in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares during the period. Finally, Strs Ohio raised its holdings in shares of Aimmune Therapeutics by 6.1% during the 2nd quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 2,000 shares during the period. Institutional investors and hedge funds own 72.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/25/aimmune-therapeutics-inc-aimt-stock-price-up-6-2.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.